FDA Advisory Committee votes in favour of the clinical benefit of Roche’s Polivy combination for people with previously untreated diffuse large B-cell lymphoma March 9, 2023March 10, 2023 by / Share This.....LinkedinTwitterFacebookGoogleEmailRelated News: FDA accepts supplemental Biologics License…CHMP recommends EU approval of Roche’s Polivy…Roche’s Polivy combination approved by European…Roche presents new and updated data for Polivy in…Roche’s Polivy combination reduced the risk of…[Ad hoc announcement pursuant to Art. 53 LR] Phase…Share this:Click to share on Twitter (Opens in new window)Click to share on Facebook (Opens in new window)
